Expanded access to fosmanogepix for serious fungal infections
Treatments studied
Part of Infections clinical trials.
This program provides access to an experimental antifungal drug called fosmanogepix for people with serious or life-threatening fungal infections that haven't responded to other treatments. It's for those who have no other options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a proven or probable serious or life-threatening fungal infection
- The infection is resistant to one or more standard antifungal treatments
- You have exhausted all available treatment options, including approved drugs and clinical studies
- You qualify under the EORTC-MSGERC criteria (a standard set of rules for diagnosing fungal infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This trial studies whether IV (through a vein) fosfomycin can treat severe bacterial infections in adults. It may help people whose infection is covered by the standard fosfomycin use and who need hospital-level care.
This study compares different antifungal medicines to see which works best for a serious lung fungal infection called pulmonary mucormycosis. If you have this infection and haven't had too much prior treatment, you might be able to join.
This expanded access program provides migalastat (a pill) to people with Fabry disease who have a specific genetic mutation and cannot use standard enzyme replacement therapy. It's an option for those who need treatment and have no other alternatives.
This trial tests whether amphotericin B can treat new fungal infections that develop in people with blood cancers even after they have taken preventive antifungal medicine. It may help patients who have a confirmed or suspected fungal infection while on that prevention.
Hear when a new Invasive Fungal Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.